{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T23:47:34Z","timestamp":1792021654609,"version":"4.4.0"},"reference-count":115,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T00:00:00Z","timestamp":1752451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004515","name":"Universiti Kebangsaan Malaysia","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004515","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Deliv. and Transl. Res."],"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The pulmonary route has gained significant attention as a drug delivery method, particularly for managing respiratory diseases. This approach provides several benefits, such as rapid therapeutic action, minimized systemic exposure, improved patient adherence, and the ability to deliver high drug concentrations directly to the lungs. Advances in inhalation devices, including pressurized metered-dose inhalers (pMDIs), dry powder inhalers (DPIs), and nebulizers, have established the pulmonary route as effective for administering both small-molecule drugs and complex biologics. Recent research has showcased the successful use of inhaled biologics such as monoclonal antibodies, nanobodies, and protein-based treatments in conditions like asthma, chronic obstructive pulmonary disease (COPD), pulmonary fibrosis, COVID-19, and respiratory syncytial virus (RSV). These treatments employ innovative mechanisms, such as muco-trapping and immune modulation, to optimize site-specific drug delivery and minimize systemic side effects. As technologies for pulmonary administration continue to evolve, they provide a non-invasive and highly promising platform for enhancing respiratory therapies and broadening the applications of biologics.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s13346-025-01909-6","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T19:57:29Z","timestamp":1752523049000},"page":"4098-4114","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Inhaled biologics for respiratory diseases: clinical potential and emerging technologies"],"prefix":"10.1007","volume":"15","author":[{"given":"Nur Adania","family":"Shaibie","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nur Dini Fatini","family":"Mohammad Faizal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fhataheya","family":"Buang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teerapol","family":"Srichana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-1328","authenticated-orcid":false,"given":"Mohd Cairul Iqbal","family":"Mohd Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,14]]},"reference":[{"key":"1909_CR1","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ejpb.2022.11.006","volume":"181","author":"A Mayor","year":"2022","unstructured":"Mayor A, et al. Inhaled IgG1 antibodies: the buffering system is an important driver of stability during mesh-nebulization. Eur J Pharm Biopharm. 2022;181:173\u201382.","journal-title":"Eur J Pharm Biopharm"},{"issue":"1","key":"1909_CR2","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","volume":"74","author":"A Sandra","year":"2022","unstructured":"Sandra A, et al. Inhaled medicines: past, present, and future. Pharmacol Rev. 2022;74(1):48.","journal-title":"Pharmacol Rev"},{"issue":"8","key":"1909_CR3","doi-asserted-by":"publisher","first-page":"647","DOI":"10.4155\/tde-2017-0037","volume":"8","author":"SP Newman","year":"2017","unstructured":"Newman SP. Drug delivery to the lungs: challenges and opportunities. Therapeutic Delivery. 2017;8(8):647\u201361.","journal-title":"Therapeutic Delivery"},{"key":"1909_CR4","doi-asserted-by":"crossref","unstructured":"LeMessurier KS, et al. Respiratory barrier as a safeguard and regulator of defense against influenza A virus and Streptococcus pneumoniae. Front Immunol. 2020;11.","DOI":"10.3389\/fimmu.2020.00003"},{"key":"1909_CR5","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-9798-5_1","volume":"2059","author":"KK Jain","year":"2020","unstructured":"Jain KK. An overview of drug delivery systems. Methods Mol Biol. 2020;2059:1\u201354.","journal-title":"Methods Mol Biol"},{"key":"1909_CR6","doi-asserted-by":"publisher","first-page":"1207641","DOI":"10.3389\/fimmu.2023.1207641","volume":"14","author":"J Plichta","year":"2023","unstructured":"Plichta J, Kuna P, Panek M. Biologic drugs in the treatment of chronic inflammatory pulmonary diseases: recent developments and future perspectives. Front Immunol. 2023;14:1207641.","journal-title":"Front Immunol"},{"issue":"1","key":"1909_CR7","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.xphs.2019.05.031","volume":"109","author":"DR Goulet","year":"2020","unstructured":"Goulet DR, Atkins WM. Considerations for the design of Antibody-Based therapeutics. J Pharm Sci. 2020;109(1):74\u2013103.","journal-title":"J Pharm Sci"},{"issue":"2","key":"1909_CR8","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/S0928-0987(00)00166-4","volume":"11","author":"VP Torchilin","year":"2000","unstructured":"Torchilin VP. Drug targeting. Eur J Pharm Sci. 2000;11(2):S81\u201391.","journal-title":"Eur J Pharm Sci"},{"key":"1909_CR9","doi-asserted-by":"publisher","first-page":"120268","DOI":"10.1016\/j.ijpharm.2021.120268","volume":"596","author":"FB Arslan","year":"2021","unstructured":"Arslan FB, Ozturk Atar K, Calis S. Antibody-mediated drug delivery. Int J Pharm. 2021;596:120268.","journal-title":"Int J Pharm"},{"issue":"8","key":"1909_CR10","doi-asserted-by":"publisher","first-page":"e014380","DOI":"10.1161\/CIRCIMAGING.122.014380","volume":"15","author":"EA Hermann","year":"2022","unstructured":"Hermann EA, et al. Pulmonary blood volume among older adults in the community: the MESA lung study. Circ Cardiovasc Imaging. 2022;15(8):e014380.","journal-title":"Circ Cardiovasc Imaging"},{"key":"1909_CR11","doi-asserted-by":"crossref","unstructured":"Chow MYT, Pan HW, Lam JKW. W.S.F. Wong, Editor. Chapter Ten - Delivery technology of inhaled therapy for asthma and COPD, in Advances in Pharmacology. Academic; 2023;273\u2013311.","DOI":"10.1016\/bs.apha.2023.03.001"},{"issue":"1","key":"1909_CR12","first-page":"2732017","volume":"2018","author":"JM Borghardt","year":"2018","unstructured":"Borghardt JM, Kloft C, Sharma A. Inhaled therapy in respiratory disease: the complex interplay of pulmonary kinetic processes. Can Respir J. 2018;2018(1):2732017.","journal-title":"Can Respir J"},{"key":"1909_CR13","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.addr.2020.12.004","volume":"169","author":"C Cruz-Teran","year":"2021","unstructured":"Cruz-Teran C, et al. Challenges and opportunities for antiviral monoclonal antibodies as COVID-19 therapy. Adv Drug Deliv Rev. 2021;169:100\u201317.","journal-title":"Adv Drug Deliv Rev"},{"key":"1909_CR14","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.jconrel.2020.11.057","volume":"329","author":"SK Lai","year":"2021","unstructured":"Lai SK, McSweeney MD, Pickles RJ. Learning from past failures: challenges with monoclonal antibody therapies for COVID-19. J Controlled Release. 2021;329:87\u201395.","journal-title":"J Controlled Release"},{"key":"1909_CR15","first-page":"576","volume-title":"Pharmacokinetics of monoclonal antibodies","author":"JT Ryman","year":"2017","unstructured":"Ryman JT, Meibohm B. Pharmacokinetics of monoclonal antibodies. Volume 6. CPT: Pharmacometrics & Systems Pharmacology; 2017. pp. 576\u201388. 9."},{"key":"1909_CR16","doi-asserted-by":"crossref","unstructured":"O\u2019Byrne PM, et al. Development of an inhaled anti-TSLP therapy for asthma. Volume 78. Pulmonary Pharmacology & Therapeutics; 2023. p. 102184.","DOI":"10.1016\/j.pupt.2022.102184"},{"key":"1909_CR17","doi-asserted-by":"crossref","unstructured":"Das SC, et al. P. Kesharwani, S. Taurin, and K. Greish, Editors Chap. 14 - Nanomedicine in pulmonary delivery. Theory and applications of nonparenteral nanomedicines. Academic; 2021;319\u201354.","DOI":"10.1016\/B978-0-12-820466-5.00014-4"},{"key":"1909_CR18","doi-asserted-by":"publisher","first-page":"114097","DOI":"10.1016\/j.addr.2021.114097","volume":"182","author":"S Haddadzadegan","year":"2022","unstructured":"Haddadzadegan S, Dorkoosh F, Bernkop-Schn\u00fcrch A. Oral delivery of therapeutic peptides and proteins: technology landscape of lipid-based nanocarriers. Adv Drug Deliv Rev. 2022;182:114097.","journal-title":"Adv Drug Deliv Rev"},{"issue":"2","key":"1909_CR19","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1007\/s11095-012-0891-5","volume":"30","author":"NK Kunda","year":"2013","unstructured":"Kunda NK, et al. Nanocarriers targeting dendritic cells for pulmonary vaccine delivery. Pharm Res. 2013;30(2):325\u201341.","journal-title":"Pharm Res"},{"key":"1909_CR20","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jconrel.2014.10.003","volume":"196","author":"L Guilleminault","year":"2014","unstructured":"Guilleminault L, et al. Fate of inhaled monoclonal antibodies after the deposition of aerosolized particles in the respiratory system. J Controlled Release. 2014;196:344\u201354.","journal-title":"J Controlled Release"},{"issue":"6","key":"1909_CR21","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1046\/j.1365-2125.2003.01892.x","volume":"56","author":"NR Labiris","year":"2003","unstructured":"Labiris NR, Dolovich MB. Pulmonary drug delivery. Part I: physiological factors affecting therapeutic effectiveness of aerosolized medications. Br J Clin Pharmacol. 2003;56(6):588\u201399.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"1909_CR22","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1080\/17425247.2018.1502267","volume":"15","author":"N Osman","year":"2018","unstructured":"Osman N, et al. Carriers for the targeted delivery of aerosolized macromolecules for pulmonary pathologies. Expert Opin Drug Deliv. 2018;15(8):821\u201334.","journal-title":"Expert Opin Drug Deliv"},{"key":"1909_CR23","doi-asserted-by":"crossref","unstructured":"Yang Z et al. Inhalable antibodies for the treatment of COVID-19. Innov, 2022;3(6).","DOI":"10.1016\/j.xinn.2022.100328"},{"issue":"3","key":"1909_CR24","doi-asserted-by":"publisher","first-page":"100218","DOI":"10.1016\/j.xcrm.2021.100218","volume":"2","author":"MS Piepenbrink","year":"2021","unstructured":"Piepenbrink MS, et al. Therapeutic activity of an inhaled potent SARS-CoV-2 neutralizing human monoclonal antibody in hamsters. Cell Rep Med. 2021;2(3):100218.","journal-title":"Cell Rep Med"},{"key":"1909_CR25","doi-asserted-by":"publisher","first-page":"114530","DOI":"10.1016\/j.ejpb.2024.114530","volume":"204","author":"K Berkenfeld","year":"2024","unstructured":"Berkenfeld K, et al. Formulation strategies, Preparation methods, and devices for pulmonary delivery of biologics. Eur J Pharm Biopharm. 2024;204:114530.","journal-title":"Eur J Pharm Biopharm"},{"issue":"3","key":"1909_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s13346-022-01251-1","volume":"13","author":"S Alipour","year":"2023","unstructured":"Alipour S, Mahmoudi L, Ahmadi F. Pulmonary drug delivery: an effective and convenient delivery route to combat COVID-19. Drug Delivery Translational Res. 2023;13(3):705\u201315.","journal-title":"Drug Delivery Translational Res"},{"issue":"2","key":"1909_CR27","first-page":"336","volume":"12","author":"E Parhizkar","year":"2021","unstructured":"Parhizkar E, et al. Carrier effect in development of Rifampin loaded proliposome for pulmonary delivery: a quality by design study. Adv Pharm Bull. 2021;12(2):336.","journal-title":"Adv Pharm Bull"},{"issue":"1","key":"1909_CR28","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/nrd2153","volume":"6","author":"JS Patton","year":"2007","unstructured":"Patton JS, Byron PR. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov. 2007;6(1):67\u201374.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"1909_CR29","doi-asserted-by":"publisher","first-page":"14260","DOI":"10.1038\/s41598-025-86458-1","volume":"15","author":"R Dey","year":"2025","unstructured":"Dey R, Patni HK, Anand S. Improved aerosol deposition predictions in human upper respiratory tract using coupled mesh phantom-based computational model. Sci Rep. 2025;15(1):14260.","journal-title":"Sci Rep"},{"key":"1909_CR30","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.addr.2016.04.012","volume":"102","author":"A Costa","year":"2016","unstructured":"Costa A, et al. The formulation of nanomedicines for treating tuberculosis. Adv Drug Deliv Rev. 2016;102:102\u201315.","journal-title":"Adv Drug Deliv Rev"},{"issue":"1","key":"1909_CR31","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1089\/jamp.2019.1564","volume":"34","author":"EL Kolewe","year":"2020","unstructured":"Kolewe EL, Feng Y, Fromen CA. Realizing Lobe-Specific aerosol targeting in a 3D-Printed in vitro lung model. J Aerosol Med Pulmonary Drug Delivery. 2020;34(1):42\u201356.","journal-title":"J Aerosol Med Pulmonary Drug Delivery"},{"issue":"26, 2024","key":"1909_CR32","doi-asserted-by":"publisher","first-page":"p307","DOI":"10.1146\/annurev-bioeng-110122-010848","volume":"26","author":"IR Woodward","year":"2024","unstructured":"Woodward IR, Fromen CA. Recent developments in aerosol pulmonary drug delivery: new technologies, new cargos, and new targets. Annu Rev Biomed Eng. 2024;26(26, 2024):p307\u2013330.","journal-title":"Annu Rev Biomed Eng"},{"key":"1909_CR33","doi-asserted-by":"publisher","first-page":"114831","DOI":"10.1016\/j.addr.2023.114831","volume":"199","author":"ER Sudduth","year":"2023","unstructured":"Sudduth ER, et al. Aerosol pulmonary immune engineering. Adv Drug Deliv Rev. 2023;199:114831.","journal-title":"Adv Drug Deliv Rev"},{"issue":"11","key":"1909_CR34","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/s41563-022-01360-9","volume":"21","author":"F Zhang","year":"2022","unstructured":"Zhang F, et al. Nanoparticle-modified microrobots for in vivo antibiotic delivery to treat acute bacterial pneumonia. Nat Mater. 2022;21(11):1324\u201332.","journal-title":"Nat Mater"},{"issue":"10","key":"1909_CR35","doi-asserted-by":"publisher","first-page":"2004574","DOI":"10.1002\/advs.202004574","volume":"8","author":"E Bolli","year":"2021","unstructured":"Bolli E, et al. Targeted repolarization of Tumor-Associated macrophages via Imidazoquinoline-Linked nanobodies. Adv Sci. 2021;8(10):2004574.","journal-title":"Adv Sci"},{"key":"1909_CR36","doi-asserted-by":"crossref","unstructured":"Rodr\u00edguez-Nava C et al. Mechanisms of action and limitations of monoclonal antibodies and single chain fragment variable (scFv) in the treatment of Cancer. Biomedicines, 2023;11(6).","DOI":"10.3390\/biomedicines11061610"},{"key":"1909_CR37","doi-asserted-by":"publisher","first-page":"120107","DOI":"10.1016\/j.ijpharm.2020.120107","volume":"593","author":"S Mahri","year":"2021","unstructured":"Mahri S, et al. PEGylation of Recombinant human deoxyribonuclease I decreases its transport across lung epithelial cells and uptake by macrophages. Int J Pharm. 2021;593:120107.","journal-title":"Int J Pharm"},{"key":"1909_CR38","doi-asserted-by":"publisher","first-page":"114904","DOI":"10.1016\/j.addr.2023.114904","volume":"199","author":"M Shi","year":"2023","unstructured":"Shi M, McHugh KJ. Strategies for overcoming protein and peptide instability in biodegradable drug delivery systems. Adv Drug Deliv Rev. 2023;199:114904.","journal-title":"Adv Drug Deliv Rev"},{"issue":"5","key":"1909_CR39","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1080\/17425247.2020.1739021","volume":"17","author":"M Cazzola","year":"2020","unstructured":"Cazzola M, et al. Advances in pulmonary drug delivery devices for the treatment of chronic obstructive pulmonary disease. Expert Opin Drug Deliv. 2020;17(5):635\u201346.","journal-title":"Expert Opin Drug Deliv"},{"issue":"2","key":"1909_CR40","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1007\/s40199-024-00520-3","volume":"32","author":"N Islam","year":"2024","unstructured":"Islam N, Suwandecha T, Srichana T. Dry powder inhaler design and particle technology in enhancing pulmonary drug deposition: challenges and future strategies. DARU J Pharm Sci. 2024;32(2):761\u201379.","journal-title":"DARU J Pharm Sci"},{"issue":"10","key":"1909_CR41","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1002\/jps.2600601028","volume":"60","author":"JH Bell","year":"1971","unstructured":"Bell JH, Hartley PS, Cox JSG. Dry powder aerosols I: A new powder inhalation device. J Pharm Sci. 1971;60(10):1559\u201364.","journal-title":"J Pharm Sci"},{"key":"1909_CR42","doi-asserted-by":"publisher","first-page":"107435","DOI":"10.1016\/j.rmed.2023.107435","volume":"219","author":"F Lavorini","year":"2023","unstructured":"Lavorini F, et al. A narrative review on the synchrobreathe\u2122: A novel breath-actuated pressurised metered-dose inhaler for the treatment of obstructive airway diseases. Respir Med. 2023;219:107435.","journal-title":"Respir Med"},{"key":"1909_CR43","doi-asserted-by":"publisher","first-page":"114580","DOI":"10.1016\/j.addr.2022.114580","volume":"191","author":"S H\u00e4u\u00dfermann","year":"2022","unstructured":"H\u00e4u\u00dfermann S, Arendsen LJ, Pritchard JN. Smart dry powder inhalers and intelligent adherence management. Adv Drug Deliv Rev. 2022;191:114580.","journal-title":"Adv Drug Deliv Rev"},{"key":"1909_CR44","doi-asserted-by":"crossref","unstructured":"Wang J et al. Advancing treatment strategies: A comprehensive review of drug delivery innovations for chronic inflammatory respiratory diseases. Pharmaceutics, 2023;15(8).","DOI":"10.3390\/pharmaceutics15082151"},{"issue":"6","key":"1909_CR45","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1517\/17425247.2015.995087","volume":"12","author":"AR Martin","year":"2015","unstructured":"Martin AR and W.H. and, Finlay. Nebulizers for drug delivery to the lungs. Expert Opin Drug Deliv. 2015;12(6):889\u2013900.","journal-title":"Expert Opin Drug Deliv"},{"key":"1909_CR46","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ejim.2020.02.023","volume":"75","author":"C Sorino","year":"2020","unstructured":"Sorino C, et al. Inhalation therapy devices for the treatment of obstructive lung diseases: the history of inhalers towards the ideal inhaler. Eur J Intern Med. 2020;75:15\u20138.","journal-title":"Eur J Intern Med"},{"key":"1909_CR47","doi-asserted-by":"crossref","unstructured":"Kumar N, et al. Chap. 11 - Nanoparticle-based macromolecule drug delivery to lungs. In: Dua K, et al. editors. Targeting chronic inflammatory lung diseases using advanced drug delivery systems. Academic; 2020;227\u201359.","DOI":"10.1016\/B978-0-12-820658-4.00011-X"},{"issue":"5","key":"1909_CR48","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1089\/jamp.2018.1508","volume":"32","author":"W Longest","year":"2019","unstructured":"Longest W, Spence B, Hindle M. Devices for improved delivery of nebulized pharmaceutical aerosols to the lungs. J Aerosol Med Pulm Drug Deliv. 2019;32(5):317\u201339.","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"1909_CR49","doi-asserted-by":"publisher","first-page":"108601","DOI":"10.1016\/j.biopha.2019.108601","volume":"112","author":"A Chandel","year":"2019","unstructured":"Chandel A, et al. Recent advances in aerosolised drug delivery. Biomed Pharmacother. 2019;112:108601.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"1909_CR50","doi-asserted-by":"publisher","first-page":"2804","DOI":"10.1007\/s10439-015-1335-2","volume":"43","author":"DR Farkas","year":"2015","unstructured":"Farkas DR, Hindle M, Longest PW. Characterization of a new High-Dose dry powder inhaler (DPI) based on a fluidized bed design. Ann Biomed Eng. 2015;43(11):2804\u201315.","journal-title":"Ann Biomed Eng"},{"issue":"5","key":"1909_CR51","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1016\/j.xphs.2023.02.010","volume":"112","author":"M Ibrahim","year":"2023","unstructured":"Ibrahim M, et al. Protein aggregates in inhaled biologics: challenges and considerations. J Pharm Sci. 2023;112(5):1341\u20134.","journal-title":"J Pharm Sci"},{"issue":"3","key":"1909_CR52","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1007\/s12325-021-02034-9","volume":"39","author":"D Cataldo","year":"2022","unstructured":"Cataldo D, et al. How to choose the right inhaler using a Patient-Centric approach?? Adv Therapy. 2022;39(3):1149\u201363.","journal-title":"Adv Therapy"},{"issue":"5","key":"1909_CR53","doi-asserted-by":"publisher","first-page":"140","DOI":"10.18773\/austprescr.2024.046","volume":"47","author":"D Rigby","year":"2024","unstructured":"Rigby D. Inhaler device selection for people with asthma or chronic obstructive pulmonary disease. Aust Prescr. 2024;47(5):140\u20137.","journal-title":"Aust Prescr"},{"key":"1909_CR54","doi-asserted-by":"crossref","unstructured":"Hickey AJ and I.E. and, Stewart. Inhaled antibodies: quality and performance considerations. Volume 18. Human Vaccines & Immunotherapeutics; 2022. p. 1940650. 2.","DOI":"10.1080\/21645515.2021.1940650"},{"issue":"2\u20133","key":"1909_CR55","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1615\/CritRevTherDrugCarrierSyst.v12.i2-3.20","volume":"12","author":"RW Niven","year":"1995","unstructured":"Niven RW. Delivery of biotherapeutics by inhalation aerosol. Crit Rev Ther Drug Carrier Syst. 1995;12(2\u20133):151\u2013231.","journal-title":"Crit Rev Ther Drug Carrier Syst"},{"issue":"1","key":"1909_CR56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ijpharm.2006.02.014","volume":"314","author":"SA Shoyele","year":"2006","unstructured":"Shoyele SA, Slowey A. Prospects of formulating proteins\/peptides as aerosols for pulmonary drug delivery. Int J Pharm. 2006;314(1):1\u20138.","journal-title":"Int J Pharm"},{"key":"1909_CR57","doi-asserted-by":"crossref","unstructured":"Liang W et al. Pulmonary Delivery Biol Drugs Pharm, 2020;12(11).","DOI":"10.3390\/pharmaceutics12111025"},{"key":"1909_CR58","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.2147\/COPD.S114034","volume":"11","author":"DP Tashkin","year":"2016","unstructured":"Tashkin DP. A review of nebulized drug delivery in COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2585\u201396.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1909_CR59","doi-asserted-by":"crossref","unstructured":"Gauvreau GM et al. Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma. Eur Respir J, 2023;61(3).","DOI":"10.1183\/13993003.01193-2022"},{"issue":"5","key":"1909_CR60","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1164\/rccm.201712-2382OC","volume":"198","author":"D Lightwood","year":"2018","unstructured":"Lightwood D, et al. Efficacy of an inhaled IL-13 antibody fragment in a model of chronic asthma. Am J Respir Crit Care Med. 2018;198(5):610\u20139.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1909_CR61","doi-asserted-by":"publisher","first-page":"5436","DOI":"10.1038\/s41598-025-89874-5","volume":"15","author":"Y Yu","year":"2025","unstructured":"Yu Y, et al. OM85 ameliorates bleomycin-induced pulmonary fibrosis in mice by inhibiting Notch expression and modulating the IFN-\u03b3\/IL-4 ratio. Sci Rep. 2025;15(1):5436.","journal-title":"Sci Rep"},{"issue":"1","key":"1909_CR62","doi-asserted-by":"publisher","first-page":"3251","DOI":"10.1038\/s41467-025-58568-x","volume":"16","author":"V Neiens","year":"2025","unstructured":"Neiens V, et al. Preclinical concept studies showing advantage of an inhaled anti-CTGF\/CCN2 protein for pulmonary fibrosis treatment. Nat Commun. 2025;16(1):3251.","journal-title":"Nat Commun"},{"issue":"1","key":"1909_CR63","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1038\/s41467-020-14344-7","volume":"11","author":"P-UC Dinh","year":"2020","unstructured":"Dinh P-UC, et al. Inhalation of lung spheroid cell secretome and exosomes promotes lung repair in pulmonary fibrosis. Nat Commun. 2020;11(1):1064.","journal-title":"Nat Commun"},{"issue":"6523","key":"1909_CR64","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1126\/science.abe4747","volume":"370","author":"Y Xiang","year":"2020","unstructured":"Xiang Y, et al. Versatile and multivalent nanobodies efficiently neutralize SARS-CoV-2. Science. 2020;370(6523):1479\u201384.","journal-title":"Science"},{"issue":"2","key":"1909_CR65","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/S2213-2600(20)30511-7","volume":"9","author":"PD Monk","year":"2021","unstructured":"Monk PD, et al. Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Respiratory Med. 2021;9(2):196\u2013206.","journal-title":"Lancet Respiratory Med"},{"issue":"1","key":"1909_CR66","doi-asserted-by":"publisher","first-page":"5191","DOI":"10.1038\/s41467-023-40933-3","volume":"14","author":"J Liu","year":"2023","unstructured":"Liu J, et al. An IgM-like inhalable ACE2 fusion protein broadly neutralizes SARS-CoV-2 variants. Nat Commun. 2023;14(1):5191.","journal-title":"Nat Commun"},{"key":"1909_CR67","doi-asserted-by":"crossref","unstructured":"McSweeney MD, et al. Stable nebulization and muco-trapping properties of regdanvimab\/IN-006 support its development as a potent, dose-saving inhaled therapy for COVID-19. Volume 8. Bioengineering & Translational Medicine; 2023. p. e10391. 1.","DOI":"10.1002\/btm2.10391"},{"issue":"5","key":"1909_CR68","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1038\/mi.2017.35","volume":"10","author":"OJ Hall","year":"2017","unstructured":"Hall OJ, Klein SL. Progesterone-based compounds affect immune responses and susceptibility to infections at diverse mucosal sites. Mucosal Immunol. 2017;10(5):1097\u2013107.","journal-title":"Mucosal Immunol"},{"issue":"1","key":"1909_CR69","doi-asserted-by":"publisher","first-page":"17241","DOI":"10.1038\/s41598-024-66439-6","volume":"14","author":"L Wang","year":"2024","unstructured":"Wang L, et al. Progesterone modulates the immune microenvironment to suppress ovalbumin-induced airway inflammation by inhibiting NETosis. Sci Rep. 2024;14(1):17241.","journal-title":"Sci Rep"},{"issue":"1","key":"1909_CR70","doi-asserted-by":"publisher","first-page":"32108","DOI":"10.1038\/s41598-024-83852-z","volume":"14","author":"Y Zhang","year":"2024","unstructured":"Zhang Y, et al. Inhalation of Patchouli essential oil alleviates airway inflammation in cigarette smoke-induced COPD mice. Sci Rep. 2024;14(1):32108.","journal-title":"Sci Rep"},{"key":"1909_CR71","doi-asserted-by":"crossref","unstructured":"Zhu J, et al. Inhaled immunoantimicrobials for the treatment of chronic obstructive pulmonary disease. Sci Adv. 2024;10(6):eabd7904.","DOI":"10.1126\/sciadv.abd7904"},{"issue":"12","key":"1909_CR72","doi-asserted-by":"publisher","first-page":"2306729","DOI":"10.1002\/advs.202306729","volume":"11","author":"MD McSweeney","year":"2024","unstructured":"McSweeney MD, et al. Inhaled Muco-Trapping monoclonal antibody effectively treats established respiratory syncytial virus (RSV) infections. Adv Sci. 2024;11(12):2306729.","journal-title":"Adv Sci"},{"issue":"2","key":"1909_CR73","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.tips.2022.11.006","volume":"44","author":"MYT Chow","year":"2023","unstructured":"Chow MYT, et al. Inhalable neutralizing antibodies\u2013 promising approach to combating respiratory viral infections. Trends Pharmacol Sci. 2023;44(2):85\u201397.","journal-title":"Trends Pharmacol Sci"},{"issue":"1","key":"1909_CR74","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/S2213-2600(20)30320-9","volume":"9","author":"S Cunningham","year":"2021","unstructured":"Cunningham S, et al. Nebulised ALX-0171 for respiratory syncytial virus lower respiratory tract infection in hospitalised children: a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respiratory Med. 2021;9(1):21\u201332.","journal-title":"Lancet Respiratory Med"},{"issue":"1","key":"1909_CR75","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1128\/AAC.01802-15","volume":"60","author":"L Detalle","year":"2016","unstructured":"Detalle L, et al. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob Agents Chemother. 2016;60(1):6\u201313.","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"1909_CR76","doi-asserted-by":"publisher","first-page":"101016","DOI":"10.1016\/j.waojou.2024.101016","volume":"18","author":"GW Canonica","year":"2025","unstructured":"Canonica GW, et al. Biologics as well as inhaled anti-asthmatic therapy achieve clinical remission: evidence from the severe asthma network in Italy (SANI). World Allergy Organ J. 2025;18(1):101016.","journal-title":"World Allergy Organ J"},{"key":"1909_CR77","doi-asserted-by":"crossref","unstructured":"Liaqat A et al. Evidence-Based approach of biologic therapy in bronchial asthma. J Clin Med, 2023;12(13).","DOI":"10.3390\/jcm12134321"},{"issue":"2","key":"1909_CR78","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1056\/NEJMra2032506","volume":"386","author":"GG Brusselle","year":"2022","unstructured":"Brusselle GG, Koppelman GH. Biologic therapies for severe asthma. N Engl J Med. 2022;386(2):157\u201371.","journal-title":"N Engl J Med"},{"issue":"11","key":"1909_CR79","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1080\/14656566.2024.2389258","volume":"25","author":"BJH Dierick","year":"2024","unstructured":"Dierick BJH, et al. Reshaping respiratory care: potential advances in inhaled pharmacotherapy in asthma. Expert Opin Pharmacother. 2024;25(11):1507\u201316.","journal-title":"Expert Opin Pharmacother"},{"key":"1909_CR80","doi-asserted-by":"crossref","unstructured":"Menzella F. Baseline characteristics of patients enrolled in clinical trials of biologics for severe asthma as potential predictors of outcomes. J Clin Med, 2023;12(4).","DOI":"10.3390\/jcm12041546"},{"key":"1909_CR81","doi-asserted-by":"crossref","unstructured":"Pelaia C et al. Tezepelumab: A potential new biological therapy for severe refractory asthma. Int J Mol Sci, 2021;22(9).","DOI":"10.3390\/ijms22094369"},{"issue":"12","key":"1909_CR82","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1111\/all.15473","volume":"77","author":"G Varricchi","year":"2022","unstructured":"Varricchi G, et al. Biologics and airway remodeling in severe asthma. Allergy. 2022;77(12):3538\u201352.","journal-title":"Allergy"},{"key":"1909_CR83","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1016\/j.rmed.2019.05.005","volume":"153","author":"MG Matera","year":"2019","unstructured":"Matera MG, et al. Monoclonal antibodies for severe asthma: Pharmacokinetic profiles. Respir Med. 2019;153:3\u201313.","journal-title":"Respir Med"},{"issue":"1","key":"1909_CR84","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s12931-018-0859-z","volume":"19","author":"A Matucci","year":"2018","unstructured":"Matucci A, Vultaggio A, Danesi R. The use of intravenous versus subcutaneous monoclonal antibodies in the treatment of severe asthma: a review. Respir Res. 2018;19(1):154.","journal-title":"Respir Res"},{"key":"1909_CR85","doi-asserted-by":"publisher","unstructured":"Pelaia C, et al. Tezepelumab: A potential new biological therapy for severe refractory asthma. Int J Mol Sci. 2021;22. https:\/\/doi.org\/10.3390\/ijms22094369","DOI":"10.3390\/ijms22094369"},{"key":"1909_CR86","unstructured":"Malik B, Ghatol A. Understanding How Monoclonal Antibodies Work, in StatPearls. 2023, StatPearls Publishing Copyright \u00a9 2023, StatPearls Publishing LLC.: Treasure Island (FL)."},{"issue":"3","key":"1909_CR87","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jmb.2012.11.036","volume":"425","author":"D Lightwood","year":"2013","unstructured":"Lightwood D, et al. The discovery, engineering and characterisation of a highly potent Anti-Human IL-13 fab fragment designed for administration by inhalation. J Mol Biol. 2013;425(3):577\u201393.","journal-title":"J Mol Biol"},{"key":"1909_CR88","doi-asserted-by":"crossref","unstructured":"Wolters PJ, Collard HR, Jones KD. Pathogenesis of Idiopathic Pulmonary Fibrosis. Annual Review of Pathology: Mechanisms of Disease, 2014;9:157\u2013179.","DOI":"10.1146\/annurev-pathol-012513-104706"},{"key":"1909_CR89","doi-asserted-by":"publisher","unstructured":"Murthy P, et al. An overview of herbal medicines for idiopathic pulmonary fibrosis. Processes. 2022;10. https:\/\/doi.org\/10.3390\/pr10061131","DOI":"10.3390\/pr10061131"},{"issue":"1","key":"1909_CR90","doi-asserted-by":"publisher","first-page":"10742","DOI":"10.1038\/s41598-020-67598-y","volume":"10","author":"Y Zhuang","year":"2020","unstructured":"Zhuang Y, et al. Incidence and impact of extra-pulmonary organ failures on hospital mortality in acute exacerbation of idiopathic pulmonary fibrosis. Sci Rep. 2020;10(1):10742.","journal-title":"Sci Rep"},{"key":"1909_CR91","doi-asserted-by":"crossref","unstructured":"Cottin V, Maher T. Long-term clinical and real-world experience with Pirfenidone in the treatment of idiopathic pulmonary fibrosis. Eur Respiratory Rev. 2015;24(135):58\u201364.","DOI":"10.1183\/09059180.00011514"},{"issue":"1","key":"1909_CR92","doi-asserted-by":"publisher","first-page":"12528","DOI":"10.1038\/s41598-023-39101-w","volume":"13","author":"M Kato","year":"2023","unstructured":"Kato M, et al. Nintedanib administration after the onset of acute exacerbation of interstitial lung disease in the real world. Sci Rep. 2023;13(1):12528.","journal-title":"Sci Rep"},{"key":"1909_CR93","doi-asserted-by":"crossref","unstructured":"Sousa De S\u00e1 Marques M, et al. Antifibrotic therapy on progressive fibrotic lung disease non-IPF\u2013 a retrospective cohort. Eur Respir J. 2022;60(suppl 66):1403.","DOI":"10.1183\/13993003.congress-2022.1403"},{"issue":"1","key":"1909_CR94","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1038\/s41598-022-05138-6","volume":"12","author":"S Sakamoto","year":"2022","unstructured":"Sakamoto S, et al. New risk scoring system for predicting 3-month mortality after acute exacerbation of idiopathic pulmonary fibrosis. Sci Rep. 2022;12(1):1134.","journal-title":"Sci Rep"},{"issue":"7","key":"1909_CR95","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1080\/14728222.2022.2114897","volume":"26","author":"P Spagnolo","year":"2022","unstructured":"Spagnolo P, et al. The role of immune response in the pathogenesis of idiopathic pulmonary fibrosis: Far beyond the Th1\/Th2 imbalance. Expert Opin Ther Targets. 2022;26(7):617\u201331.","journal-title":"Expert Opin Ther Targets"},{"issue":"5","key":"1909_CR96","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.arcmed.2008.02.005","volume":"39","author":"A Sumida","year":"2008","unstructured":"Sumida A, et al. Th1\/Th2 immune response in lung fibroblasts in interstitial lung disease. Arch Med Res. 2008;39(5):503\u201310.","journal-title":"Arch Med Res"},{"issue":"22","key":"1909_CR97","doi-asserted-by":"publisher","first-page":"eabh0319","DOI":"10.1126\/sciadv.abh0319","volume":"7","author":"S Nambulli","year":"2021","unstructured":"Nambulli S, et al. Inhalable nanobody (PiN-21) prevents and treats SARS-CoV-2 infections in Syrian hamsters at ultra-low doses. Sci Adv. 2021;7(22):eabh0319.","journal-title":"Sci Adv"},{"issue":"2","key":"1909_CR98","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1164\/rccm.201312-2235OC","volume":"190","author":"R Djukanovi\u0107","year":"2014","unstructured":"Djukanovi\u0107 R, et al. The effect of inhaled IFN-\u03b2 on worsening of asthma symptoms caused by viral infections. A randomized trial. Am J Respir Crit Care Med. 2014;190(2):145\u201354.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1909_CR99","doi-asserted-by":"publisher","first-page":"55","DOI":"10.7224\/1537-2073.2013-006","volume":"16","author":"ML Filipi","year":"2014","unstructured":"Filipi ML, et al. Nurses\u2019 perspective on approaches to limit Flu-Like symptoms during interferon therapy for multiple sclerosis. Int J MS Care. 2014;16(1):55\u201360.","journal-title":"Int J MS Care"},{"key":"1909_CR100","doi-asserted-by":"crossref","unstructured":"Reynolds S, et al. Antiviral biomarkers are upregulated in sputum cells following administration of inhaled interferon beta to COPD patients. European Respiratory Society; 2019.","DOI":"10.1183\/13993003.congress-2019.OA263"},{"issue":"2","key":"1909_CR101","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.cell.2020.02.052","volume":"181","author":"M Hoffmann","year":"2020","unstructured":"Hoffmann M, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271\u2013e2808.","journal-title":"Cell"},{"issue":"6485","key":"1909_CR102","doi-asserted-by":"publisher","first-page":"1444","DOI":"10.1126\/science.abb2762","volume":"367","author":"R Yan","year":"2020","unstructured":"Yan R, et al. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science. 2020;367(6485):1444\u20138.","journal-title":"Science"},{"issue":"7798","key":"1909_CR103","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","volume":"579","author":"P Zhou","year":"2020","unstructured":"Zhou P, et al. A pneumonia outbreak associated with a new coronavirus of probable Bat origin. Nature. 2020;579(7798):270\u20133.","journal-title":"Nature"},{"issue":"2","key":"1909_CR104","doi-asserted-by":"publisher","first-page":"1939605","DOI":"10.1080\/21645515.2021.1939605","volume":"18","author":"A Schaefer","year":"2022","unstructured":"Schaefer A, Lai SK. The biophysical principles underpinning muco-trapping functions of antibodies. Hum Vaccin Immunother. 2022;18(2):1939605.","journal-title":"Hum Vaccin Immunother"},{"issue":"9859","key":"1909_CR105","doi-asserted-by":"publisher","first-page":"2095","DOI":"10.1016\/S0140-6736(12)61728-0","volume":"380","author":"R Lozano","year":"2012","unstructured":"Lozano R, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the global burden of disease study 2010. Lancet. 2012;380(9859):2095\u2013128.","journal-title":"Lancet"},{"issue":"7","key":"1909_CR106","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1038\/nrd4025","volume":"12","author":"PJ Barnes","year":"2013","unstructured":"Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discovery. 2013;12(7):543\u201359.","journal-title":"Nat Rev Drug Discovery"},{"issue":"4","key":"1909_CR107","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1517\/14728222.8.4.265","volume":"8","author":"MG Belvisi","year":"2004","unstructured":"Belvisi MG, H.D. J., and M.A. and, Birrell. New anti-inflammatory therapies and targets for asthma and chronic obstructive pulmonary disease. Expert Opin Ther Targets. 2004;8(4):265\u201385.","journal-title":"Expert Opin Ther Targets"},{"issue":"1","key":"1909_CR108","doi-asserted-by":"publisher","first-page":"14703","DOI":"10.1038\/s41598-024-65763-1","volume":"14","author":"J Shin","year":"2024","unstructured":"Shin J, et al. Survival benefit of inhaled corticosteroids in patients with chronic obstructive pulmonary disease: a nationwide cohort study. Sci Rep. 2024;14(1):14703.","journal-title":"Sci Rep"},{"issue":"1","key":"1909_CR109","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s10020-024-00883-y","volume":"30","author":"B Xie","year":"2024","unstructured":"Xie B, et al. Progesterone (P4) ameliorates cigarette smoke-induced chronic obstructive pulmonary disease (COPD). Mol Med. 2024;30(1):123.","journal-title":"Mol Med"},{"issue":"1","key":"1909_CR110","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1086\/314567","volume":"179","author":"LL Han","year":"1999","unstructured":"Han LL, Alexander JP, Anderson LJ. Respiratory syncytial virus pneumonia among the elderly: an assessment of disease burden. J Infect Dis. 1999;179(1):25\u201330.","journal-title":"J Infect Dis"},{"issue":"9725","key":"1909_CR111","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1016\/S0140-6736(10)60206-1","volume":"375","author":"H Nair","year":"2010","unstructured":"Nair H, et al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010;375(9725):1545\u201355.","journal-title":"Lancet"},{"issue":"6","key":"1909_CR112","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1056\/NEJMoa0804877","volume":"360","author":"CB Hall","year":"2009","unstructured":"Hall CB, et al. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009;360(6):588\u201398.","journal-title":"N Engl J Med"},{"issue":"8","key":"1909_CR113","first-page":"769","volume":"56","author":"AL Rogovik","year":"2010","unstructured":"Rogovik AL, et al. Palivizumab for the prevention of respiratory syncytial virus infection. Can Fam Physician. 2010;56(8):769\u201372.","journal-title":"Can Fam Physician"},{"issue":"9","key":"1909_CR114","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1056\/NEJMoa2110275","volume":"386","author":"LL Hammitt","year":"2022","unstructured":"Hammitt LL, et al. Nirsevimab for prevention of RSV in healthy Late-Preterm and term infants. N Engl J Med. 2022;386(9):837\u201346.","journal-title":"N Engl J Med"},{"key":"1909_CR115","doi-asserted-by":"crossref","unstructured":"Ananworanich J, Heaton PM. Bringing preventive RSV monoclonal antibodies to infants in Low- and Middle-Income countries: challenges and opportunities. Vaccines (Basel), 2021;9(9).","DOI":"10.3390\/vaccines9090961"}],"updated-by":[{"DOI":"10.1007\/s13346-025-01985-8","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:00:00Z","timestamp":1758931200000}}],"container-title":["Drug Delivery and Translational Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01909-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13346-025-01909-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13346-025-01909-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T07:03:55Z","timestamp":1759993435000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13346-025-01909-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,14]]},"references-count":115,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1909"],"URL":"https:\/\/doi.org\/10.1007\/s13346-025-01909-6","relation":{},"ISSN":["2190-393X","2190-3948"],"issn-type":[{"value":"2190-393X","type":"print"},{"value":"2190-3948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,14]]},"assertion":[{"value":"23 June 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":3,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":4,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The article\u2019s PDF file was corrected.","order":5,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2025","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s13346-025-01985-8","URL":"https:\/\/doi.org\/10.1007\/s13346-025-01985-8","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approvals were required for this review and no human subjects were involved.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No consents were required for this review and no human subjects were involved.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}